Activity Overview
Prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains a leading cause of cancer-related morbidity and mortality. Although PSMA PET imaging and PSMA-directed radioligand therapy (RLT) have improved diagnostic and treatment options, clinicians continue to face gaps in knowledge related to patient selection, sequencing, toxicity management, and equitable access to these evolving therapies
This case-based, interactive program is designed to enhance clinician competence and support evidence-based integration of PSMA-directed imaging and RLT into prostate cancer care.
This educational activity is an archive of the live virtual symposium held on April 1, 2026.
Target Audience
This educational program is directed toward medical oncologists, radiation oncologists, nuclear medicine specialists, advanced practice providers, oncology nurses, and other health care practitioners involved in the management of genitourinary cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the role of PSMA PET/CT in diagnosis, staging, and response assessment across the prostate cancer disease continuum
- Apply evidence-based strategies to integrate and sequence PSMA-directed radioligand therapy (RLT) in prostate cancer care
- Implement best practices to manage treatment-related toxicities associated with PSMA-RLT
- Identify and address barriers to equitable access and delivery of PSMA-targeted therapies in patients with prostate cancer
Mary-Ellen Taplin, MD
Chair, Executive Committee for Clinical Research
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consultant/Advisory Boards: Amgen, Astellas, AstraZeneca, Curio Science, Dava Oncology, Flare Therapeutics, Geode Therapeutics, GlaxoSmithKline, Janssen, Laekna, Novartis; Grant/Research/Clinical Trial Support: Janssen
Jeremie Calais, MD, PhD
Director, Clinical Research and Theranostics Programs
Associate Professor
Ahmanson Translational Theranostics Division
Department of Molecular and Medical Pharmacology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Advanced Accelerator Applications, Amgen, Astellas, Bayer, Blue Earth Diagnostics, Coretag, Curium Pharma, DS Pharma, FibroGen, GE Healthcare, IBA Radio Pharma, IsoRay, Janssen, Lantheus, Lightpoint Medical, Mariana, Monrol, Novartis, Nucleus RadioPharma, Pfizer, POINT Biopharma, Progenics, RadioMedix, Radiopharm Theranostics, Sanofi, Siemens-Varian, SOFIE, Telix Pharmaceutical; Grant/Research Funding: FUSION, Lantheus, Novartis, POINT Biopharma, TELIX
Himanshu Nagar, MD, MS
Director of Genitourinary Cancers
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Boston Scientific, Elektra; Grant/Research Funding: Angiodynamics, Elekta, Lantheus, Teleflex
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here